We are an iconic provider of hospital-based healthcare, striving to deliver an exceptional standard of care
We comprise several hospitals, health centres, a nationally accredited education provider and a world-class research institute
We are a nationally accredited, hospital-based Registered Training Organisation - the only one of its kind in Queensland
We are part of a collaborative research institute with The University of Queensland and founding partner of the Translational Research Institute
In the last decade an increasing number of Australian patients have been diagnosed with autoimmune associated epilepsy - a potentially treatable form of the neurological disease that is caused by a change in the body’s immune function.
The main feature of autoimmune epilepsy is refractory seizures, and many patients appear to respond well to some immunotherapy treatments, but there are currently no clear guidelines on which patients should be tested for this epilepsy sub-type.
Mater Researcher Dr Lisa Gillinder has authored a newly published paper that provides new insights into how patients with autoimmune epilepsy are identified and potentially treated.
“We reviewed all the prior literature in the field of autoimmune associated epilepsy in a bid to provide clarity around which epilepsy patients are most likely to be affected by autoimmunity and therefore might benefit from immune based treatments,” Dr Gillinder said.
“Studies into this epilepsy sub-type have reported varying numbers of cases, but there is emerging evidence that the condition may be more common among patients attending epilepsy clinics than previously thought.”
Dr Gillinder said the literature review suggests that autoimmune testing could be a valuable tool for the early diagnosis of this type of epilepsy.
“Our review surmises that autoimmune testing has an important role in this disease, because early diagnosis can affect treatment options and better management of seizures,” she said.
“Our team also identified large gaps in the current knowledge of the condition and we outline a new framework to help focus further research that will improve the understanding of autoimmune seizures. This will help ensure that patients are diagnosed correctly and have access to the best available treatments for their epilepsy.”
The review was conducted in collaboration with Dr Claude Steriade and Prof Jacqueline French from New York University and Prof Jeffrey Britton from the Mayo Clinic.
The paper has recently been published in the journal JAMA Neurology. https://jamanetwork.com/journals/jamaneurology/fullarticle/2784256
07 3163 1524
07 3163 6142
Mater Women’s Health Physiotherapist Megan Newell is about to embark on her first missionary effort to support women in need and the clinicians caring for them.
Brisbane volunteers Shaqireen Azam and Malihah Rustam are more than just students, they’re friends who share a passion for helping people in their community.
Shaune Watt is a man motivated by personal experience. The arrival of his son Noah, born prematurely and critically ill more than a decade ago, inspired Shaune to ...
Mater is pioneering therapeutic horticulture for its hospital staff with the launch of an edible garden pilot project, designed to reduce burnout and enhance the ...